An open-source AI tool can help predict renal function decline in prostate cancer patients undergoing lutetium-177 (Lu-177) radiopharmaceutical therapy, according to a study published February 25 in Radiology.
The tool automatically segments total kidney volume on standard CT images, with measurements predicting deterioration of renal function 12 months after patients initiated therapy, noted lead authors Lisa Steinhelfer, MD, and Friederike Jungmann, MD, of the Technical University of Munich in Germany, and colleagues.
“The expanding use of lutetium-177 prostate-specific membrane antigen-I&T radioligand therapy [Lu-177 PSMA-I&T, Pluvicto] in advanced prostate cancer highlights the critical need for reliable biomarkers to predict and manage treatment-related toxicities,” the group wrote.
Lu-177 PSMA-I&T is an…